Translational science in medicine: Implications for the pharmaceutical industry

International Journal of Pharmaceutical Medicine

Volumn 20, Issue 5, 2006, Pages 303-310

  Wehling, Martin ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BACLOFEN; BIOLOGICAL MARKER; CORTICOSTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; ROSUVASTATIN; THROMBOXANE; TRASTUZUMAB;

ATHEROMA; BLOOD PRESSURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFECT; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; IMAGING; METHODOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

EID: 33845350345     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200620050-00004     Document Type: Review

References (19)

1. US FDA. The critical path to new medical products [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/ [Accessed 2006 Jun 15]
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Discov 2004; 3: 711-5
3. Reputation of pharmaceutical companies, while still poor, improves sharply for second year in a row [online]. Available from URL: http://www.harrisinteractive. com/news/allnewsbydate.asp?.NewsID=1051 [Accessed 2006 Jun 14]
4. Fleming A. How I discovered penicillin. J Med (Oporto) 1950 May 6; 15 (380): 683
5. Encyclopaedia Britannica [online]. Available from URL: http://www.britannica.com/eb/article-9066286 [Accessed 2006 Aug 29]
6. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2: 566-80
7. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109 (21 Suppl. 1): II18-26
8. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints. Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
9. Rolan P, Atkinson Jr AJ, Lesko LJ, et al. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003; 73: 284-91
10. Wehling M. Translational medicine: can it really facilitate the transition of research "from bench to bedside"? Eur J Clin Pharmacol 2006 Feb; 62 (2): 91-5
11. Hatsukami TS, Saam T, Yuyan C, et al. Rosuvastatin treatment arrests the progression of carotid atherosclerosis in moderately hypercholesterolaemic subjects: a high-resolution magnetic resonance imaging trial. 75th European Atherosclerosis Society Congress; 2005 Apr 23-26; Prague, Czech Republic
12. Vasan R. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-62
13. Early Detection Research Network. Science components [online]. Available from URL: http://edrn.nci.nih.gov/about-edrn/scicomponents [Accessed 2006 Jun 15]
14. Ohlstein EH, Johnson AG, Elliott JD, et al. New strategies in drug discovery. Methods Mol Biol 2006; 316: 1-11
15. Bilello JA. The agony and ecstasy of "OMIC" technologies in drug development. Curr Mol Med 2005; 5: 39-52
16. Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov 2005; 4: 345-50
17. B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402
18. Leyland-Jones B. Maximizing the response to herceptin therapy through optimal use and patient selection. Anticancer Drugs 2001; 12 Suppl. 4: S11-7
19. CenterWatch. Drugs approved by FDA (2006) [online]. Available from URL: http://www.centerwatch.com/patient/drugs/druglist.html [Accessed 2006 Jun 15]